Artelo Biosciences Plunges 28.08% on Public Offering Announcement

On September 4, 2025, Artelo Biosciences experienced a significant drop of 47.72% in pre-market trading, marking a notable decline in its stock performance.

Artelo Biosciences' stock fell 28.08% pre-market after announcing a public offering to fund ART27.13 development for cancer anorexia-cachexia syndrome (CACS). The offering, under a 2023 SEC-registered shelf, aims to support clinical trials and ART27.13's Phase 2 trial showed significant weight gain and lean mass improvements.

Interim data revealed +6.38% weight gain at the highest ART27.13 dose vs. -5.42% placebo, prompting dose escalation plans with acceptable safety. The company also explores digital assets in its treasury strategy while targeting unmet needs in anorexia, cancer, and other conditions.